Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
CRISPR Therapeutics
Pharma
With 64 centers activated, bluebird is ready to grow Lyfgenia
Bluebird has started its first patient on its sickle cell disease gene therapy Lyfgenia. And, with 64 treatment centers active, there's room to grow.
Kevin Dunleavy
May 9, 2024 1:40pm
Vertex's Casgevy launch progresses as CF drugs post solid growth
May 7, 2024 11:23am
NICE rejects Vertex, CRISPR's Casgevy, asks for more data
Mar 14, 2024 11:24am
'The Top Line': A closer look at new drug approvals in 2023
Jan 19, 2024 6:00am
JPM24: Bluebird CEO defends Lyfgenia pricing premium, EU retreat
Jan 10, 2024 7:10pm
JPM24, Day 3: CRISPR, BioMarin, Alkermes and more
Jan 10, 2024 7:00pm